Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT02583477 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02583477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02583477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Completed
Start date
March 25, 2016
Completion date
July 9, 2018
Enrollment
23 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic ductal adenocarcinoma